Cholesterol Management

New research examines the connection between cholesterol and liver damage in high-risk patients.

A recent CDC examination revealed rates of American adults eligible for cholesterol-lowering drugs, and how many of these adults are not taking them.

A recent report from a non-profit, independant research group addresses the cost-effectiveness and budgetary impact of treatment with PCSK9 inhibitors.

An FDA advisory committee has voted to recommend approval of a new drug for the long-term treatment of patients with hypercholesterolemia and dyslipidemia.

Researchers studied the impact of replacing saturated fatty acids with unsaturated fatty acids on cholesterol.